Avalo Therapeutics, Inc. (AVTX)

Market Cap	52.51M
Revenue (ttm)	441,000
Net Income (ttm)	73.01M
Shares Out	10.83M
EPS (ttm)	-4.90
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	32,225
Open	4.785
Previous Close	4.750
Day's Range	4.630 - 4.990
52-Week Range	3.390 - 16.000
Beta	0.78
Analysts	Strong Buy
Price Target	31.00 (+539.18%)
Earnings Date	Aug 11, 2025

About AVTX

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. Its lead asset includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1β, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 15, 2015
• Employees: 23
• Stock Exchange: NASDAQ
• Ticker Symbol: AVTX
• Website: https://www.avalotx.com

Financial Performance

In 2024, Avalo Therapeutics's revenue was $441,000, a decrease of -77.08% compared to the previous year's $1.92 million. Losses were -$35.13 million, 11.4% more than in 2023.

Analyst Summary

According to 7 analysts, the average rating for AVTX stock is "Strong Buy." The 12-month stock price target is $31.0, which is an increase of 539.18% from the latest price.

Price Target

$31.0

(539.18% upside)

Analyst Consensus: Strong Buy